Tina Vilsbøll

Research interests

Publications

• Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

  JCI Insight · 2022 · 10.1172/jci.insight.159863

• Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1901118

• Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals

  American Journal of Physiology-Gastrointestinal and Liver Physiology · 2019 · 10.1152/ajpgi.00358.2018

• Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease

  Molecular Systems Biology · 2019 · 10.15252/msb.20188793

• Glucagon-like peptide 1 in health and disease

  Nature Reviews Endocrinology · 2018 · 10.1038/s41574-018-0016-2

• Recovery of gut microbiota of healthy adults following antibiotic exposure

  Nature Microbiology · 2018 · https://doi.org/10.1038/s41564-018-0257-9

• Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

  Diabetes Obesity and Metabolism · 2017 · 10.1111/dom.13172

• Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

  PLoS ONE · 2016 · 10.1371/journal.pone.0166125

• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1607141

• Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)

  Diabetes Care · 2014 · 10.2337/dc14-0785

• Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

  Diabetologia · 2013 · 10.1007/s00125-013-2841-0

• Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

  BMJ · 2012 · https://doi.org/10.1136/bmj.d7771

• Glucose-Dependent Insulinotropic Polypeptide

  Diabetes · 2011 · 10.2337/db11-0979

• Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

  Diabetes Care · 2011 · 10.2337/dc11-s227

• The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action

  Diabetes · 2010 · 10.2337/db09-1414

• Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

  Diabetes Obesity and Metabolism · 2009 · 10.1111/j.1463-1326.2009.01173.x

• Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

  Diabetologia · 2008 · 10.1007/s00125-008-1195-5

• Reduced Incretin Effect in Type 2 Diabetes

  Diabetes · 2007 · 10.2337/db07-0100

• Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

  Diabetes Care · 2007 · 10.2337/dc06-2593

• Incretins, insulin secretion and Type 2 diabetes mellitus

  Diabetologia · 2004 · 10.1007/s00125-004-1342-6

• Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption

  Journal of Bone and Mineral Research · 2003 · 10.1359/jbmr.2003.18.12.2180

• Incretin Secretion in Relation to Meal Size and Body Weight in Healthy Subjects and People with Type 1 and Type 2 Diabetes Mellitus

  The Journal of Clinical Endocrinology & Metabolism · 2003 · 10.1210/jc.2002-021873

• Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects

  The Journal of Clinical Endocrinology & Metabolism · 2003 · 10.1210/jc.2002-021053

• Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

  Regulatory Peptides · 2003 · 10.1016/s0167-0115(03)00111-3

• Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

  Diabetes · 2001 · https://doi.org/10.2337/diabetes.50.3.609

Current projects

No projects listed.